<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gurjar, Mukund K.</style></author><author><style face="normal" font="default" size="100%">Wakharkar, Radhika D.</style></author><author><style face="normal" font="default" size="100%">Singh, Anu T.</style></author><author><style face="normal" font="default" size="100%">Jaggi, Manu</style></author><author><style face="normal" font="default" size="100%">Borate, Hanumant B.</style></author><author><style face="normal" font="default" size="100%">Shinde, Popat D.</style></author><author><style face="normal" font="default" size="100%">Verma, Ritu</style></author><author><style face="normal" font="default" size="100%">Rajendran, Praveen</style></author><author><style face="normal" font="default" size="100%">Dutt, Sarjana</style></author><author><style face="normal" font="default" size="100%">Singh, Gurvinder</style></author><author><style face="normal" font="default" size="100%">Sanna, Vinod K.</style></author><author><style face="normal" font="default" size="100%">Singh, Manoj K.</style></author><author><style face="normal" font="default" size="100%">Srivastava, Sanjay K.</style></author><author><style face="normal" font="default" size="100%">Mahajan, Vishal A.</style></author><author><style face="normal" font="default" size="100%">Jadhav, Vinod H.</style></author><author><style face="normal" font="default" size="100%">Dutta, Kakali</style></author><author><style face="normal" font="default" size="100%">Krishnan, Karthik</style></author><author><style face="normal" font="default" size="100%">Chaudhary, Anika</style></author><author><style face="normal" font="default" size="100%">Agarwal, Shiv K.</style></author><author><style face="normal" font="default" size="100%">Mukherjee, Rama</style></author><author><style face="normal" font="default" size="100%">Burman, Anand C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Synthesis and evaluation of 4/5-hydroxy-2,3-diaryl(substituted)-cyclopent-2-en-1-ones as cis-restricted analogues of combretastatin A-4 as novel anticancer agents</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Medicinal Chemistry</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2007</style></year><pub-dates><date><style  face="normal" font="default" size="100%">APR</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">8</style></number><publisher><style face="normal" font="default" size="100%">AMER CHEMICAL SOC</style></publisher><pub-location><style face="normal" font="default" size="100%">1155 16TH ST, NW, WASHINGTON, DC 20036 USA</style></pub-location><volume><style face="normal" font="default" size="100%">50</style></volume><pages><style face="normal" font="default" size="100%">1744-1753</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;A new series of 2,3-diaryl-4/5-hydroxy-cyclopent-2-en-1-one analogues replacing the cis double bond of combretastatin A-4 (CA-4) by 4/5-hydroxy cyclopentenone moieties was designed and synthesized. The analogues displayed potent cytotoxic activity (IC50 &amp;lt; 1 mu g/mL) against a panel of human cancer cell lines and endothelial cells. The most potent analogues 11 and 42 belonging to the 5-hydroxy cyclopentenone class were further evaluated for their mechanism of action. Both of the analogues led to cell cycle arrest at G2/M phase and induced apoptosis in endothelial cells. Antitubulin property of 42 was superior to 11 and comparable to CA-4. The compound 42 had better aqueous solubility, metabolic stability, and pharmacokinetic profile than CA-4 and also demonstrated significant tumor regression in the human colon xenograft model. Our data suggests that cis-restricted analogues of CA-4 are a new class of molecules that have the potential to be developed as novel agents for the treatment of cancer.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">8</style></issue><work-type><style face="normal" font="default" size="100%">Article</style></work-type><custom3><style face="normal" font="default" size="100%">&lt;p&gt;Foreign&lt;/p&gt;</style></custom3><custom4><style face="normal" font="default" size="100%">5.589</style></custom4></record></records></xml>